Misonix Trains More Than 50 Spine Surgeons on the BoneScalpel® at International Spine Meeting

FARMINGDALE, N.Y., Sept. 15, 2015 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and other surgical specialties, successfully trained more than 50 spine surgeons at a BoneScalpel hands-on workshop during the EuroSpine 2015 meeting in Copenhagen, Denmark last week.

"The EuroSpine meeting was another of our perfect venues for surgeons from around the world to learn about the BoneScalpel and participate in a hands-on demonstration," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "With the addition of 50 more spine surgeons trained, we expect this EuroSpine workshop to make a positive impact on our International sales momentum. This workshop was a follow on to the IMAST workshop where more than 70 surgeons trained in Malaysia this past July."

The workshop, entitled, "Ultrasonic BoneScalpel Techniques for Treating the Complex Spine," was presented by the following group of leading spine surgeons:

• Daniel Rosenthal, MD, Hochtaunusklinik, Bad Homburg, Germany
• Dr. Martin Wilby, The Walton Centre, Liverpool, UK
• Dr. Simon Clark, The Walton Centre, Liverpool, UK

During the workshop, the surgeon presenters reviewed their clinical experiences with BoneScalpel in degenerative and complex spinal procedures, demonstrating the surgical benefits over traditional technologies while leading their colleagues through a hands-on demonstration. The surgeons noted particularly the benefits realized using the BoneScalpel of significant savings in operative blood loss, higher safety when working around vital structures such as the dura, and the overall time savings in procedures.

Dr. Rosenthal said, "At our hands-on workshop, spine surgeons learned several BoneScalpel techniques and surgical benefits for using the device in many different spinal procedures such as laminectomy and facetectomy. I conveyed to my colleagues that I use this device in all my procedures as it protects soft tissue and reduces bone bleeding."

"BoneScalpel is the biggest advancement that I have seen in spine surgery in more than five years," said Dr. Simon Clark, consultant neurosurgeon at The Walton Centre in Liverpool, UK.

The EuroSpine meeting is a three-day international forum with leading spine surgeons discussing and demonstrating innovative surgical technologies that help improve patient care.

About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

SOURCE Misonix, Inc.

Related Links

http://www.misonix.com